[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100351774":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":32,"centralContacts":38,"locations":43,"responsibleParty":62,"collaborators":66,"id":68,"slug":69,"hasResults":70,"nctId":71,"briefTitle":72,"officialTitle":73,"acronym":25,"eligibilityCriteria":74,"healthyVolunteers":70,"sex":75,"minAge":76,"maxAge":25,"enrollmentInfo":77,"targetDuration":25,"studyType":80,"phases":81,"briefSummary":83,"conditions":84,"keywords":87,"overallStatus":46,"whyStopped":25,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":98,"locationsCount":99},{"fullName":5,"class":6},"George Washington University","OTHER",[8,15],{"label":9,"type":10,"description":11,"interventionNames":12},"Visit 1 Randomization","EXPERIMENTAL","At visit 1subjects will receive one of two interventions: either Oxytocin Intranasal spray (40 IU) or Placebo Intranasal spray. Subjects will be blinded as to which drug they are receiving.",[13,14],"Drug: Oxytocin","Drug: Placebo",{"label":16,"type":10,"description":17,"interventionNames":18},"Visit 2 Crossover Randomization","At visit 2 subjects will receive the opposite intervention from the one they received at visit 1: either Oxytocin Intranasal spray (40 IU) or Placebo Intranasal spray. Subjects will be blinded as to which drug they are receiving.",[13,14],[20,26],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","Oxytocin","40 IU administered intranasal, within 1 hour prior to sleeping for 14 days",[9,16],null,{"type":21,"name":27,"description":28,"armGroupLabels":29,"otherNames":30},"Placebo","Intranasal spray to mimic Oxytocin intranasal spray",[9,16],[31],"Placebo (for Oxytocin)",[33,36],{"name":34,"affiliation":5,"role":35},"Vivek Jain, MD","PRINCIPAL_INVESTIGATOR",{"name":37,"affiliation":5,"role":35},"David Mendelowitz, PhD",[39],{"name":34,"role":40,"phone":41,"phoneExt":25,"email":42},"CONTACT","202-741-2237","vjain@mfa.gwu.edu",[44],{"facility":45,"status":46,"city":47,"state":48,"zip":49,"country":50,"countryCode":51,"cosmosGeoPoint":52,"geoPoint":57,"contacts":58},"Medical Faculty Associates","RECRUITING","Washington D.C.","District of Columbia","20037","United States","US",{"type":53,"coordinates":54},"Point",[55,56],-77.03637,38.89511,{"lat":56,"lon":55},[59,60],{"name":34,"role":40,"phone":41,"phoneExt":25,"email":42},{"name":37,"role":40,"phone":61,"phoneExt":25,"email":25},"202-994-3466",{"type":63,"investigatorFullName":64,"investigatorTitle":65,"investigatorAffiliation":5,"oldNameTitle":25,"oldOrganization":25},"SPONSOR_INVESTIGATOR","Vivek Jain","Principal Investigator",[67],{"name":5,"class":6},"100351774","phase-1-benefits-of-oxytocin-in-obstructive-sleep-apnea-osa-patients-using-continuous-positive-airway-pressure-cpap-machine-100351774",false,"NCT03860233","Benefits of Oxytocin in Obstructive Sleep Apnea (OSA) Patients Using Continuous Positive Airway Pressure (CPAP) Machine","Benefits of Oxytocin in OSA Patients Using CPAP","Inclusion Criteria:\n\n* Men or women 18 years of age or older.\n\nExclusion Criteria:\n\n* subjects not willing to or otherwise unable to use CPAP for treatment of OSA.\n* Presence of other sleep disorders\n* Pregnant or breastfeeding women\n* Women of child-bearing age (WOCBA) not willing or unable to use an accepted method to avoid pregnancy for the entire duration of the study\n* Prisoners or subjects who are involuntarily incarcerated\n* Subjects who are compulsorily detain or treatment of either a psychiatric or physical (i.e. infectious disease) illness\n* Patients unable to give consent because of a language barrier, or other reason.","ALL","18 Years",{"count":78,"type":79},40,"ESTIMATED","INTERVENTIONAL",[82],"PHASE1","This study will investigate if an intra-nasal nose spray of the drug oxytocin can decrease the amount of pressure needed from the automatic Continuous Positive Airway Pressure (CPAP) device while sleeping decreasing some of the harmful effects of low oxygen in people with sleep apnea.\n\nThis study will last 35 nights and involves spending three nights in the sleep lab at George Washington University. There are no additional costs to participants and no compensation for being involved in the study.",[85,86],"Sleep Apnea","Sleep Apnea, Obstructive",[88,89,22],"Continuous Positive Airway Pressure","CPAP","2026-04-28",{"date":92,"type":93},"2026-05-04","ACTUAL",{"date":95,"type":93},"2019-03-04",{"date":97,"type":79},"2026-12-31",{"name":64,"class":6},1]